Soleno Therapeutics Inc - SIC # 8731 - COMMERCIAL PHY_SICAL AND BIOLOGICAL RESEARCH

Ticker Exchange SIC # Website Latest Ticker
SLNO Nasdaq 8731 https://soleno.life/

Select one of the four (4) financial statement analysis reports below to view the ratio analysis report for your selected company:

Financial Analysis - Public Company vs Industry Ratio Analysis
Financial Analysis - Public Company
Industry Ratios Analysis
Public Company vs Public Company

Latest Headlines for Soleno Therapeutics Inc

Soleno Therapeutics to Present at 2024 Cantor Global Healthcare Conference - Sep 16th, 2024 8:05 pm
High Growth Tech Stocks To Watch In September 2024 - Sep 3rd, 2024 10:02 am
Soleno Stock Up as FDA Accepts PWS Drug NDA Under Priority Review - Aug 28th, 2024 2:25 pm
Soleno wins FDA priority review for Prader-Willi therapy - Aug 28th, 2024 2:13 pm
Soleno Therapeutics, Inc. (SLNO): One of Oppenheimer’s Top Stock Picks For the Next 12 Months - Aug 28th, 2024 12:51 am
Soleno Therapeutics Announces U.S. FDA Acceptance for Filing and Priority Review of NDA for DCCR (Diazoxide Choline) Extended-Release Tablets in Prader-Willi Syndrome - Aug 27th, 2024 12:00 pm
Soleno Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - Aug 19th, 2024 8:17 pm
Soleno Therapeutics Announces Updates to its Board of Directors - Aug 15th, 2024 12:00 pm
Soleno Therapeutics Provides Corporate Update and Reports Second Quarter 2024 Financial Results - Aug 7th, 2024 8:05 pm
When Can We Expect A Profit From Soleno Therapeutics, Inc. (NASDAQ:SLNO)? - Jul 29th, 2024 10:46 am
These Stock Winners Are ‘Strong Buys’ With More Room Left to Run - Jul 17th, 2024 12:56 pm
Soleno Therapeutics Announces Submission of New Drug Application to the U.S. FDA for DCCR (Diazoxide Choline) Extended-Release Tablets for the Treatment of Prader-Willi Syndrome - Jun 28th, 2024 12:00 pm
Soleno Therapeutics Set to Join Russell 3000® Index - Jun 4th, 2024 12:00 pm
Soleno Therapeutics Announces Oral Presentation featuring DCCR (Diazoxide Choline) Extended-Release Tablets in Prader-Willi Syndrome at ENDO 2024 - May 22nd, 2024 8:05 pm
Soleno Therapeutics to Participate in Upcoming Investor Conferences - May 22nd, 2024 12:00 pm
Soleno Therapeutics Stands with the Prader-Willi Syndrome Community - May 15th, 2024 12:00 pm
Soleno Therapeutics Provides Corporate Update and Reports First Quarter 2024 Financial Results - May 9th, 2024 8:05 pm
While institutions invested in Soleno Therapeutics, Inc. (NASDAQ:SLNO) benefited from last week's 4.8% gain, private equity firms stood to gain the most - May 8th, 2024 11:50 am
Soleno Therapeutics Announces Pricing of Approximately $138 Million Public Offering Of Common Stock - May 3rd, 2024 2:32 am
Soleno Therapeutics Announces Proposed Public Offering of Common Stock - May 2nd, 2024 8:01 pm